Personalis (NASDAQ:PSNL) Coverage Initiated by Analysts at Lake Street Capital

Lake Street Capital assumed coverage on shares of Personalis (NASDAQ:PSNL) in a research note released on Tuesday, Benzinga reports. The brokerage issued a buy rating and a $4.00 price target on the stock.

Separately, Needham & Company LLC reiterated a buy rating and set a $3.50 price objective on shares of Personalis in a report on Thursday, April 11th.

Personalis Price Performance

NASDAQ PSNL opened at $1.47 on Tuesday. The firm has a market cap of $74.24 million, a P/E ratio of -0.65 and a beta of 1.95. Personalis has a one year low of $0.89 and a one year high of $2.60. The stock’s 50-day moving average is $1.45 and its 200-day moving average is $1.43.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $19.68 million during the quarter, compared to the consensus estimate of $19.56 million. Personalis had a negative return on equity of 61.42% and a negative net margin of 147.38%. Equities analysts anticipate that Personalis will post -1.58 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. State of Michigan Retirement System grew its stake in Personalis by 11.3% in the first quarter. State of Michigan Retirement System now owns 493,798 shares of the company’s stock valued at $736,000 after purchasing an additional 50,000 shares in the last quarter. Quadrature Capital Ltd bought a new position in Personalis in the fourth quarter valued at approximately $152,000. Bruce & Co. Inc. grew its stake in Personalis by 100.0% in the fourth quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock valued at $630,000 after purchasing an additional 150,000 shares in the last quarter. ARK Investment Management LLC grew its stake in Personalis by 16.6% in the fourth quarter. ARK Investment Management LLC now owns 6,671,545 shares of the company’s stock valued at $14,010,000 after purchasing an additional 952,118 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC bought a new position in Personalis in the third quarter valued at approximately $36,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.